Vitamin D3 (Cholecalciferol)

This is the core, non-negotiable role and the reason reference intakes exist. Vitamin D is required for active intestinal calcium and phosphate absorption; severe deficiency causes defective bone mineralization — rickets in children, osteomalacia in adults — which supplementation corrects. Reference bodies set an RDA of 15 mcg (600 IU)/day for adults to 70 and 20 mcg (800 IU)/day beyond 70 specifically to maintain bone health, and clinical guidelines define deficiency (commonly 25(OH)D < 30 nmol/L / 12 ng/mL) and its repletion ^{1,19Reference 1National Institutes of Health · 2024ReviewVitamin D — Fact Sheet for Health Professionals — [authoritative review]. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/View study →Reference 19Holick et al. · 2011Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline — [clinical guideline]View study →}.

The 2024 Endocrine Society guideline reaffirms empiric supplementation in children and adolescents (1–18 y) to prevent nutritional rickets ^{20Reference 20Demay et al. · 2024Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline — [clinical guideline]View study →}.

The benefit here is a repletion effect: it is large in the deficient and absent in the already-replete.

Gap: the effect is entirely deficiency-dependent — it says nothing about supplementing people who already have adequate status.

The best-evidenced “extra” benefit. A 2017 individual-participant-data meta-analysis of 25 RCTs (~11,000 participants) found vitamin D supplementation modestly reduced the risk of at least one acute respiratory infection, with the protective effect concentrated in those who were most deficient at baseline and who received daily or weekly (not large bolus) dosing ^{2Reference 2Martineau et al. · 2017Meta-analysisVitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data — [IPD meta-analysis]View study →}.

A 2021 aggregate-data meta-analysis of 43 trials broadly reproduced a small protective effect while narrowing the effect size and again favoring regular, moderate dosing ^{10Reference 10Jolliffe et al. · 2021Meta-analysisVitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from RCTs — [meta-analysis]View study →}.

For COVID-19 specifically the signal did not hold up: a randomized trial of a single 200,000 IU bolus in hospitalized moderate-to-severe patients showed no effect on length of stay or other outcomes ^{11Reference 11Murai et al. · 2021RCTEffect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate-to-severe COVID-19 — [RCT, null]View study →}.

The 2024 Endocrine Society guideline cites respiratory-infection reduction as part of its rationale for empiric supplementation in children/adolescents ^{20Reference 20Demay et al. · 2024Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline — [clinical guideline]View study →}.

Gap: absolute risk reductions are small, driven by deficient subgroups, and abolished by high intermittent bolus dosing — not a general “immune booster” for replete people.

Fracture data split cleanly by population and co-treatment. In generally healthy, replete midlife-and-older adults, the large VITAL trial (2,000 IU/day D3, ~25,000 people) found no reduction in total, non-vertebral, or hip fractures ^{3Reference 3LeBoff et al. · 2022RCTSupplemental vitamin D and incident fractures in midlife and older adults (VITAL) — [RCT]View study →}.

Benefit appears only in the classic at-risk setting: pooled and meta-analytic data show vitamin D plus calcium reduces hip and total fractures in older, often institutionalized and vitamin-D-deficient adults, whereas vitamin D alone does not ^{5,6Reference 5Yao et al. · 2019Meta-analysisVitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis — [meta-analysis]View study →Reference 6Bischoff-Ferrari et al. · 2012A pooled analysis of vitamin D dose requirements for fracture prevention — [pooled analysis of RCTs]View study →}.

Consistent with a lack of skeletal benefit in the replete, a meta-analysis of bone mineral density found no clinically meaningful BMD improvement from vitamin D supplementation ^{4Reference 4Reid et al. · 2014Meta-analysisEffects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis — [meta-analysis]View study →}.

Gap: the benefit requires co-administered calcium and a deficient, high-risk population; vitamin D alone in replete adults does nothing for fractures or BMD.

A pre-specified ancillary of VITAL is the most encouraging “new” signal. Over ~5 years, 2,000 IU/day D3 (with or without omega-3) reduced incident confirmed autoimmune disease versus placebo, with the effect strengthening in later follow-up years ^{17Reference 17Hahn et al. · 2022RCTVitamin D and marine omega-3 fatty acid supplementation and incident autoimmune disease (VITAL) — [RCT]View study →}. The relative reduction (~22%) is meaningful but the absolute numbers are small, and this is a single trial in older adults.

Gap: one unreplicated RCT with a modest absolute effect; needs confirmation before it changes practice.

The clearest example of a trial and a meta-analysis reading differently. The purpose-built D2d trial randomized adults with prediabetes to 4,000 IU/day D3 or placebo and found no significant reduction in progression to type 2 diabetes on its primary endpoint ^{15Reference 15Pittas et al. · 2019RCTVitamin D supplementation and prevention of type 2 diabetes (D2d) — [RCT, null]View study →}.

However, a 2023 individual-participant-data meta-analysis pooling D2d with two other prediabetes trials found that vitamin D did reduce progression to diabetes in people with prediabetes (a modest but statistically significant relative reduction) ^{21Reference 21Pittas et al. · 2023Meta-analysisVitamin D and risk for type 2 diabetes in people with prediabetes: a systematic review and meta-analysis of individual participant data — [IPD meta-analysis]View study →}.

On that basis the 2024 Endocrine Society guideline suggests empiric supplementation specifically for adults with high-risk prediabetes ^{20Reference 20Demay et al. · 2024Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline — [clinical guideline]View study →}.

This is a genuine repletion-adjacent signal in a defined at-risk group — not a general metabolic benefit.

Gap: the effect is confined to high-risk prediabetes and is modest; the single dedicated RCT was null on its primary endpoint, and there is no benefit for metabolic health in the general replete population.

The most instructive reversal in the field. An influential 2009 meta-analysis found higher-dose daily vitamin D (700–1,000 IU) reduced falls in older adults ^{7Reference 7Bischoff-Ferrari et al. · 2009Meta-analysisFall prevention with supplemental and active forms of vitamin D: a meta-analysis of RCTs — [meta-analysis]View study →}, and this fed guideline enthusiasm. Larger, better-designed modern data undercut it: VITAL found 2,000 IU/day did not reduce falls ^{9Reference 9LeBoff et al. · 2020RCTVITAL: effects of vitamin D supplements on risk of falls — [RCT]View study →}, and — importantly — high intermittent dosing can cause harm, with a trial of monthly 60,000 IU increasing falls versus lower dosing ^{8Reference 8Bischoff-Ferrari et al. · 2016RCTMonthly high-dose vitamin D treatment for the prevention of functional decline — [RCT, harm signal]View study →}.

The picture now is that daily physiological repletion in the deficient may modestly help, but bolus “megadosing” is counterproductive.

Gap: modern RCTs are null-to-harmful; any benefit is confined to daily repletion of deficient individuals, and high bolus doses increase falls.

Physiologically plausible, but the dedicated trial is null. VITAL-DEP randomized >18,000 adults to 2,000 IU/day D3 or placebo and found no effect on incident depression, recurrent depression, or mood scores over ~5 years ^{16Reference 16Okereke et al. · 2020RCTEffect of long-term vitamin D3 supplementation vs placebo on risk of depression (VITAL-DEP) — [RCT, null]View study →}. Trials in already-depressed or deficient populations are smaller and inconsistent.

Gap: the large prevention RCT in non-deficient adults is flatly null; there is no good evidence for supplementing replete people for mood.

Tested directly and negative for primary endpoints. VITAL found 2,000 IU/day D3 did not reduce the primary endpoints of invasive cancer incidence or major cardiovascular events over ~5 years ^{12Reference 12Manson et al. · 2019RCTVitamin D supplements and prevention of cancer and cardiovascular disease (VITAL) — [RCT]View study →}.

A weak secondary signal for reduced cancer mortality (and in some analyses advanced/metastatic cancer) exists but is hypothesis-generating, not practice-changing. The D-Health trial likewise found no mortality benefit overall ^{13Reference 13Neale et al. · 2022RCTThe D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality — [RCT]View study →} — though the 2024 Endocrine Society guideline, reading pooled data, suggests empiric supplementation in adults over 75 for its potential to lower mortality in that oldest group specifically ^{20Reference 20Demay et al. · 2024Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline — [clinical guideline]View study →}.

Gap: null for the primary cancer and CVD endpoints in a large RCT; the cancer-mortality and over-75 mortality hints are secondary/subgroup findings needing confirmation.